Synergistic effects of Paclitaxel and Doxorubicin with liposomes nanoparticles in Cancer therapy: A review
نویسندگان
1 Nukus State Pedagogical Institute, Nukus, Uzbekistan
2 Department of Pharmacology of Bukhara State Medical Institute, Bukhara, Uzbekistan
3 Department of Methods of Russian Language and Literature, Kokand State Pedagogical Institute, Kokand, Uzbekistan
4 Department of Oncology, Center for Professional Development of Medical Workers, Tashkent, Uzbekistan
5 Department of Fruits and Vegetables, Urganch State University, Uzbekistan
6 Department of Pre-School Education Metaphysics, Termez State University of Uzbekistan, , Uzbekistan
7 Department of Urology an Oncology, Fergana medical institute of public health, Fergana, Uzbekistan
8 Andijan State Institute of Foreign Languages, Uzbekistan
9 Fergana State University , Uzbekistan
10 Department of Oncology, Center for Professional Development of Medical Workers, Tashkent, Uzbekistan
11 Department of Foreign Languages in Preschool and Primary Education, Jizzakh State Pedagogical University, Uzbekistan
12 Tashkent Institute of Irrigation and Agricultural Mechanization, Engineers National Research University, Tashkent, Uzbekistan
13 Department of Chemical Technology of Oil and Gas Refining, Tashkent Institute of Chemical Technology, Tashkent, Uzbekistan
doi
10.22052/JNS.2024.02.019چکیده
Cancer treatment often faces challenges related to drug resistance, limited bioavailability, and severe side effects. Nanotechnology has emerged as a promising solution to enhance the efficacy and specificity of chemotherapeutic agents. Combining traditional anticancer drugs like Paclitaxel and Doxorubicin with lipid nanoparticles could potentially overcome these barriers and improve patient outcomes. Paclitaxel and Doxorubicin, when formulated, significantly enhance cancer therapy by improving drug delivery and reducing side effects. Combining these drugs with lipid nanoparticles further boosts their efficacy, ensuring targeted action against cancer cells. This synergistic approach offers a promising pathway towards more effective and less toxic cancer treatments. This review synthesizes recent research findings on the use of Paclitaxel and Doxorubicin with lipid nanoparticles, focusing on their combined therapeutic efficacy, mechanisms of action, and potential advantages over traditional formulations. The aim of this review paper is to explore the synergistic effects of Paclitaxel and Doxorubicin formulations when combined with lipid nanoparticles in cancer therapy. The review highlights that combining Paclitaxel and Doxorubicin with lipid nanoparticles offers significant improvements in targeted drug delivery, bioavailability, and therapeutic outcomes, paving the way for more effective and less toxic cancer treatments.
